Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Raddeanin A Improves the Therapeutic Effect of Osimertinib in NSCLC by Accelerating ROS/NLRP3-mediated Pyroptosis.

Current pharmaceutical design - 1 Jan 2023

Lin Liping, Wu Xuan, Jiang Yuanxue, Luo Xi, Cao Xiaolong

Abstract excerpt

BACKGROUND: Osimertinib (Osm) is the preferred treatment for non-small cell lung cancer (NSCLC) patients with the epidermal growth factor receptor (EGFR) T790M mutation. Nevertheless, the resistance of NSCLC cells to Osm will eventually develop, which remains the biggest obstacle to treating such diseases. Raddeanin A (RA) exhibits a potent anti-tumor effect on various types of cancer cells. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Protein Kinase Inhibitors

Share to Reactive Oxygen Species

Source

Identifiers

PMID: 37861040
DOI: 10.2174/0113816128263069231010111347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Raddeanin A Improves the Therapeutic Effect of Osimertinib in NSCLC by Accelerating ROS/NLRP3-mediated Pyroptosis.PMID 37861040Read ↗

Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 SignalingSemantic proximity Read ↗

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Semantic proximity Read ↗

Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in Non-small-cell lung cancer cells: from the insight into the gene transcriptional levelSemantic proximity Read ↗

Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway.Semantic proximity Read ↗

Corynoxine suppresses lung adenocarcinoma proliferation and metastasis via inhibiting PI3K/AKT pathway and suppressing Cyclooxygenase-2 expressionSemantic proximity Read ↗

Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1.Semantic proximity Read ↗

Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.Semantic proximity Read ↗

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.Semantic proximity Read ↗

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.Semantic proximity Read ↗

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291Semantic proximity Read ↗

USP7-mediated ERβ stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.Semantic proximity Read ↗

Guangsangon E triggers mitochondria dysfunction and mitophagy in triple‐negative breast cancer and leads to non‐apoptotic cell deathSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.